Kanada - engelska - Health Canada

sun pharma canada inc - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium) 20mg - proton-pump inhibitors

Kanada - engelska - Health Canada

sun pharma canada inc - esomeprazole (esomeprazole magnesium) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium) 40mg - proton-pump inhibitors

Kanada - engelska - Health Canada

mylan pharmaceuticals ulc - esomeprazole (esomeprazole magnesium trihydrate) - tablet (delayed-release) - 20mg - esomeprazole (esomeprazole magnesium trihydrate) 20mg - proton-pump inhibitors

Kanada - engelska - Health Canada

mylan pharmaceuticals ulc - esomeprazole (esomeprazole magnesium trihydrate) - tablet (delayed-release) - 40mg - esomeprazole (esomeprazole magnesium trihydrate) 40mg - proton-pump inhibitors

Kanada - engelska - Health Canada

mylan pharmaceuticals ulc - esomeprazole (esomeprazole magnesium) - capsule (delayed release) - 20mg - esomeprazole (esomeprazole magnesium) 20mg - proton-pump inhibitors

Kanada - engelska - Health Canada

mylan pharmaceuticals ulc - esomeprazole (esomeprazole magnesium) - capsule (delayed release) - 40mg - esomeprazole (esomeprazole magnesium) 40mg - proton-pump inhibitors

Australien - engelska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; ascorbyl palmitate; povidone; purified talc; iron oxide red; iron oxide black; lactose monohydrate; magnesium stearate; hypromellose phthalate; crospovidone; triacetin - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - omeprazole, quantity: 20 mg - tablet, enteric coated - excipient ingredients: iron oxide black; microcrystalline cellulose; povidone; iron oxide red; crospovidone; purified talc; lactose monohydrate; hypromellose phthalate; magnesium stearate; triacetin; ascorbyl palmitate - omeprazole tablets are indicated for: a. gastro-oesophageal reflux disease (gord): 1. symptomatic gord: the relief of heartburn and other symptoms associated with gord. 2. erosive oesophagitis: the treatment and prevention of relapse. b. peptic ulcers: 1. the treatment of duodenal and gastric ulcer. 2. combination therapy for the treatment of peptic ulcer disease associated with heliobacter pylori infection. 3. the treatment of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs. 4. the prevention of gastric and duodenal ulcers and erosions associated with non-steroidal anti-inflammatory drugs in patients assessed as being at high risk of gastroduodenal ulcer or complications of gastroduodenal ulcer. 5. long-term prevention of relapse in gastric and duodenal ulceration, in patients proven to be heliobacter pylori negative, or in whom eradication is inappropriate, e.g. the elderly, or ineffective. c. zollinger-ellison syndrome: the treatment of zollinger-ellison syndrome.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole sodium, quantity: 42.6 mg (equivalent: esomeprazole, qty 40 mg) - injection, powder for - excipient ingredients: disodium edetate; sodium hydroxide - ? the short-term management of gastro-oesophageal reflux disease (gord) in patients with oesophagitis and/or severe symptoms of reflux as an alternative when oral therapy is inappropriate. ? prevention of rebleeding in patients following therapeutic endoscopy for acute, bleeding gastric or duodenal ulcers. ? short-term management in patients requiring continued non-steroidal anti- inflammatory drug (nsaid) therapy when oral therapy is inappropriate: ? healing of gastric ulcers associated with nsaid therapy ? prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk ? esomeprazole sun should be replaced with oral therapy as soon as practicable.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - esomeprazole magnesium dihydrate, quantity: 21.75 mg - tablet, enteric coated - excipient ingredients: hypromellose; purified talc; hyprolose; macrogol 6000; magnesium stearate; sodium stearylfumarate; glyceryl monostearate; triethyl citrate; microcrystalline cellulose; crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; polysorbate 80; titanium dioxide; macrogol 400; iron oxide red; iron oxide yellow; maize starch; sucrose - it is indicated for:,gastro-oesophageal reflux disease (gord): treatment of erosive reflux oesophagitis, long-term management of patients with healed oesophagitis to prevent relapse and symptomatic treatment of gastro-oesophageal reflux disease (gord).,patients requiring nsaid therapy: short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy, healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy and prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion (intravenous dosage form can be available from other brands).,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion, in combination with appropriate antibiotics for: healing of duodenal ulcer associated with helicobacter pylori and eradication of helicobacter pylori in patients with active or healed peptic ulcer.